Background: Smoking is associated with a more severe disease course in people with multiple sclerosis (MS). The magnitude of effect of smoking cessation on MS progression is unknown. The aim of this study was to quantify the impact of smoking cessation on reaching MS disability milestones. Aims and Methods: This is a cross-sectional study with retrospective reports. A comprehensive smoking questionnaire was sent to 1270 patients with MS registered between 1994 and 2013 in the Nottingham University Hospital MS Clinics database. Demographic and clinical data were extracted from the clinical database. Cox proportional hazard regression was used to estimate effects of smoke-free years on the time to Expanded Disability Status Scale (EDSS) scores 4.0 and 6.0. MS Impact Scale 29 and Patient Determined Disease Steps were used to assess the physical and psychological impact of smoking. Results: Each "smoke-free year" was associated with 0.96 (95% confidence interval: 0.95 to 0.97) times decreased risk of reaching EDSS 4.0 and 0.97 (95% confidence interval: 0.95 to 0.98) times decreased risk of reaching EDSS 6.0. Nonsmokers showed a significantly lower level of disability in all the self-reported outcomes compared with current smokers.
Introduction
Multiple sclerosis (MS) is a chronic, disabling neurological condition with a 50% higher risk to occur in tobacco smokers. 1, 2 This increased susceptibility to MS in smokers declines after smoking cessation. 3 Continuing smoking after the onset of MS worsens the clinical course. 4 Smokers with MS have more severe disease 5, 6 and increased risk of reaching higher disability scores in a shorter time than nonsmokers. 7, 8 Smoking cessation is beneficial in MS, 4, 8 but the impact on reaching disability milestones has not yet been quantified. There is typically a delay between the time a preventive measure is instituted and the time positive changes become discernible. 9 How the number of smoke-free years relates to MS progression (the degree of reduction in the risk of progression in those who quit) is unknown. In this study we address this point.
We previously reported that patients who stopped smoking, whether before or after MS onset, have significantly lower risk of disability progression compared with those who continued to smoke. 4 A recent Swedish study showed a reduction in the time to secondary progressive MS (SPMS) in those who continued to smoke compared to those who quit smoking shortly after the diagnosis of MS 8 . However, those studies do not quantify the effect of smoking cessation on reaching MS-relevant disability scores. Here, we quantify this impact and aim to provide numbers for sample size calculations in smoking cessation trials.
Patient-based outcomes are increasingly used in the assessment of treatment interventions in MS. D'Hooghe et al. 10 used a self-reported assessment of disability based on Expanded Disability Status Scale (EDSS) and on the Disease Steps Scale and showed that smoking was associated with higher risk of reaching EDSS 6.0 (ie, requiring a walking aid to walk about 100 m with or without resting) in relapsing-remitting MS (RRMS). 10 There are no data on the impact of smoking in current, ex-smokers and nonsmokers with MS and the effects of smoking on the physical and psychological MS dimensions, from the perspective of patients.
Here, we study the effect of smoke-free years on MS disability milestones, and we assess the impact of smoking on physical and psychological patient-reported outcomes in a large clinic-based MS population. In particular, we examine the impact of smoking cessation after disease onset on disability progression.
Methods
We performed a questionnaire-based, cross-sectional study with retrospective reports, assessing the status and history of smoking and the impact of smoking on physical and psychological dimensions of selfreported outcomes in a specialist clinic-based MS patient population.
Setting
We used demographic and clinical data from patients registered in the Nottingham University Hospital MS Clinics database between 1994 and 2013. These clinics cover over 3000 patients and are major catchment and referral centres in East Midlands, United Kingdom. The center and patient population have been described in more detail elsewhere. 4, 11 Data regarding sex, age at last disability assessment, age at MS onset, clinical course (RRMS, SPMS; and primary progressive MS [PPMS]), duration of exposure to disease modifying treatments (DMTs), and disability as measured by EDSS 12 were obtained from the clinical database. EDSS is a disability scale, described below. This database includes on average four EDSS scores per patient. These were estimated by a neurologist during clinic visits.
Exposure and Outcomes
Smoking: In 2013, a comprehensive smoking questionnaire with questions obtained from the Health Survey for England 2010, Respiratory Health (NS) 13 and European Community Respiratory Health Survey II 14 was sent to 1270 patients with MS fulfilling the McDonald and/or Poser criteria. 15, 16 Patients were eligible to participate if they were ≥18 years old at the time of study, had clinically definite MS, and their residence details were available. Detailed data regarding individual smoking status and history were obtained. Patients were asked about the age when they started smoking regularly, the age when they cut down or stopped smoking, and the intensity of smoking (average number of cigarettes smoked per day). Regular smoking was defined by the European Community Respiratory Health Survey II criteria 14 as ≥20 packs of cigarettes or 12 oz (360 g) of tobacco in a lifetime, or ≥1 cigarette per day or 1 cigar per week for 1 year, and confirmation of smoking within the past month. A total of 411 patients had been included in our previous work. 4 Patients were grouped as nonsmokers, ex-smokers, or current smokers.
Outcome Measures
Data needed to calculate the time to disability milestones EDSS 4.0 (can walk without aid or rest for 500 m) and 6.0 (requires aid to walk about 100 m with or without resting) 12 were extracted from the clinical database. The EDSS scale ranges from 0 to 10 in increments of 0.5 units that mean higher levels of disability. 12 The EDSS steps 1.0 to 4.5 refer to people with MS who can walk without any aid, whereas steps 5.0 to 9.5 are defined by the impairment to walking. 12 The EDSS steps 4 and 6 are established milestones in clinical studies.
The physical and psychological impact of MS from patients' perspective were assessed using Multiple Sclerosis Impact Scale 29 (MSIS-29) 17 and patient determined disease steps (PDDS) 18 which are validated patient-based outcome measures. MSIS-29 accounts for MS impact on physical (20 items) and psychological (nine items) dimensions. 17 Responses use a five-point Likert type scale range from 1 to 5 (Not at all, A little, Moderately, Quite a bit, and Extremely). 17 The total score is the sum of points for all 29 questions (minimum score: 29; maximum score: 145). 17 A change of ≥8 points in MSIS-29 (0 to 145 scale) is thought to reflect clinical change. 19 A higher score corresponds to more disability. We used the average score (the overall score divided by 29) which considers the number of questions that patient has answered, as we used previously. 20 The corresponding minimally clinically meaningful change on the scale used (1 to 5) is 0.27.
PDDS is a patient-reported outcome measure that reflects motor disability 18 and focuses on how well the patients walk. It has nine ordinal levels ranging between 0 (normal) and 8 (bedridden) of which the patient chooses the one that best describes his situation. PDDS scores can be converted into classifications of mild, moderate, or severe disability. 18, 21 PDDS is a surrogate of the EDSS. 21 The higher the score, the greater the degree of disability.
The study was approved by East Midlands Research Ethics Committee Derby-1.
Statistical Analysis
To test the differences in median MSIS-29 and PDDS scores between smoking groups, we used two-sample Wilcoxon rank-sum (MannWhitney) and Kruskal-Wallis tests, and for testing the difference in proportions of males and females in different smoking categories, chisquare test was used. Median regression models were used to compare MSIS-29 and PDDS between current, ex-, and never-smokers while adjusting for disease duration, age at onset, sex, initial course (relapse onset vs. PPMS) and DMTs for ≥1 year. Median regression coefficients are interpreted like ordinary regression coefficients. Cox proportional hazard regression models were used to estimate the risk of reaching EDSS 4.0 and 6.0. To investigate effects of smoking cessation, we fit a model with smoke-free years. Final models were adjusted for potential confounders including initial course, DMT for ≥1 year, and sex. The time axis for the regression was age, with entry from date of MS onset. This ensured hazard ratios for all risk factors were adjusted for chronological age. Patients were followed to the first sustained EDSS score 4.0 or 6.0 or censored if they had not experienced the outcome by the time of last clinic visit, independent of the study end time. We did not correct for multiple comparisons as the factors analyzed were not independent.
When fitting the smoke-free years' variable in the model, we only included intensity of smoking to avoid collinearity and nonproportional hazard. Only current and ex-smokers were included in the smoke-free years analysis. The smoke-free years was set to 0 for current smokers and the interval between age at the disability milestone (if have reached the milestone) or last visit (if censored) and age at smoking cessation in ex-smokers. For example, if an individual starting smoking at age 22 had MS onset at 33, quit smoking at 47, and reached EDSS 6.0 at 55, the smoke-free years was set = 8 and smoking duration = 25 years. In models without smoke-free years, pack years were used to adjust for the impact of duration and intensity of smoking.
Statistical analyses were performed using Stata version 13.1 (StataCorp. 2013. Stata Statistical Software. College Station, Texas, United States: StataCorp LP).
Results

Patient Characteristics
We originally identified 1412 patients who attended Nottingham University MS-specific clinics between 2000 and 2013. Of those, 120 were deceased, 14 did not have clinically definite MS, eight had missing residential address, and eight questionnaires were incomplete and were excluded. In all, 680 questionnaires with full data were returned, representing a 54% response rate. Mean age was 53 (standard deviation ± 11.33) with 2:1 female:male ratio. 57% had RRMS, 33% SP MS, and 10% PPMS. Mean MS duration was 19 (±10.4) years. 54% had ≥1 year of DMT exposure.
Smoking Prevalence
62% of the patients reported they had tried tobacco at some point (ever smoked); however, 51% reported having smoked regularly (regular smokers) and were further grouped into current or exsmokers. At MS onset, 18% and 33% were ex-smokers and current smokers, respectively. At the time of the study, 35% of smokers had quit smoking and 16% were current smokers. The percentages of nonsmokers, ex-, and current smokers were different between sexes. At the time of study, 40%, 45%, and 14% of males were nonsmokers, ex-, and current smokers versus 52%, 31%, and 16% of females (p = .003). Mean age at the start of smoking was 17.5 years (standard deviation ± 4.4). Smokers smoked for an average of 22.7 (±13.4) years with average smoking intensity of 14.6 (±8.7) cigarettes per day.
MSIS-29 and PDDS Scores
The median MSIS-29 and PDDS scores are shown in Table 1 . Both the average psychological and physical MSIS-29 scales, but not the overall scale, were higher in current smokers compared to ex-smokers, who had higher scores than never smokers. The higher scores reflect a higher level of disability.
The highest impact of smoking was on the MSIS-29 psychological scale where current and ex-smokers had a 0. Both current and ex-smokers had higher PDDS scores than nonsmokers ( Table 1 ). The median adjusted PDDS score was 0.98 (95% CI: 0.53 to 1.43, p < .001) higher in current smokers compared with nonsmokers. Ex-smokers had a nonsignificant trend to a higher median PDDS score compared with nonsmokers (Coef: 0.34, 95% CI: −0.05 to 0.75, p = .08). Coefficients of differences in median MSIS-29 and PDDS scores between nonsmokers, ex-, and current smokers are shown in Table 2 .
Smoking Cessation and the Risk of Reaching EDSS Scores 4.0 and 6.0
There were no differences in the assessment frequency between smoking groups. Patients who smoked between disease onset and the time of EDSS 4.0 and 6.0 had 2.42 (95% CI: 1.63 to 3.60, p < .001) and 1.86 (95% CI: 1.19 to 2.91, p = .006) times higher risk of reaching these two milestones compared with never smokers. Total pack years smoked up to each milestone showed no significant association with disability progression. In smokers, there was a significant difference in age at EDSS scores 4 and 6 between those who continued to smoke and those who quit smoking. Age at EDSS score 4 was 41 (95% CI: 36 to 43) in continuing smokers, 43 (95% CI: 40 to 46) in those with 1 to 15 smoke-free years, and 52 (95% CI: 48 to 56) in the group with >15 smoke-free years (p < .001). The corresponding age for EDSS score 6 was 45 (95% CI: 41 to 50), 49 (95% CI: 43 to 54), and 55 (95% CI: 50 to 59), respectively (p < .001) (Figure 2 ). Each year elapsed from smoking cessation was associated with 0.96 (95% CI: 0.95 to 0.97, p < 0.001) times decreased risk of reaching EDSS 4.0 and 0.97 (95% CI: 0.95 to 0.98, p < .001) times decreased risk of reaching EDSS 6 (Table 3) . For example, an exsmoker who stopped smoking 10 years earlier than a patient who continued smoking would have 33% and 26% lower risk of reaching EDSS scores 4.0 and 6.0, respectively (calculated as 1-(HR)^10).
Discussion
In this study, we provide quantitative measures of the impact of smoking cessation on MS progression. These data are novel and can be used in smoking cessation trials in MS. We use for the first time "smoke-free years" to quantify the impact of smoking cessation on disability progression. We show that each year after smoking cessation reduces the risk of reaching disability landmarks and the reduction in the risk of reaching advanced disability is greater if implemented early.
The prevalence of smokers and the intensity of smoking in our population are close to those reported in other studies. 6, 22 16% of the patients in our cohort were current smokers at the time of the study, versus 16.7% in a study on smoking from the North American Research Committee on MS Registry, 23 15 .2% in a self-reported National MS Society Rhode Island Chapter study, 24 and 14% in a recent Swedish study. 8 Few participants began smoking after MS onset. Many ex-smokers quit after disease onset, suggesting that a diagnosis of MS may influence smoking patterns, as reported. 25 In our cohort, the proportion of smokers was higher in males. Although at the time of the study the sex-specific proportion of current smokers was close (16.5% in women vs. 14.5% in males), more women were current smokers. Smoking in women, could have a bearing on the increasing female:male ratio in MS 26 . In our population, the proportion of smokers at onset of MS was the highest (40%) in patients who had already converted to SPMS at the time of the study. The SPMS group also had the highest proportion of current smokers. Several factors can account for this. First, most people with RRMS will convert over time to SPMS, and continued smoking hastens this transition to SPMS. 6, 8 Second, people in the SPMS group are older than those in the RRMS group, and smoking prevalence was higher in the past decades. 27 Finally, people with SPMS generally have higher degrees of disability and longer disease duration than RRMS, and the use of tobacco could be a coping mechanism, as is seen in other chronic diseases. [28] [29] [30] [31] Of note, 1/3 of all patients with MS in this study were current smokers at the onset of MS. This high prevalence of smoking at onset indicates that many patients are candidates for cessation interventions.
The data used in this study are novel and come from a well-established cohort of patients with MS 4 . We estimated the risk of reaching EDSS scores of 4.0 and 6.0, which are robust outcome measures and milestones of disability in MS. Generally, MS patients reaching EDSS 4.0 have already entered secondary progression. 32 A study by Koch et al. 33 used time to EDSS 4.0 and 6.0; however, it did not find significant evidence of an association between cigarette smoking and progression. Differences in sample size (364 patients in that study, 680 in ours) and longer follow-up make our estimates more robust. Our data are in agreement with those of D'Hooghe et al., 10 who showed higher risk of reaching EDSS 6.0 among occasional and daily cigarette smokers. Importantly, by adjusting for major confounders, we show that the effect of smoking on progression is independent of disease duration, age at onset, sex, initial type of MS, and DMTs exposure. Although total pack years smoked before each disability landmark were not associated with the risk of reaching EDSS 4.0 and 6.0, the smoke-free years had an impact on reaching both outcomes. Of note, Hedstrom et al. 3 found that the risk of developing MS in people who smoke decreases slowly after cessation regardless of the dose-response association between smoking and the risk of MS.
Our findings show that 10 smoke-free years can account for a 33% and 26% lower risk of reaching EDSS scores 4.0 and 6.0 in exsmokers compared to current smokers. Interestingly, our estimated risk reduction of 33%, 10 years after smoking cessation, confirms the findings by Ramanujam et al. 8 and Hedstrom et al. 3 and suggests that the mechanism responsible for increased susceptibility to MS in smokers also impacts disease course after MS onset. The impact of smoking and smoking cessation on smoking-related diseases is time dependent. 34 Our findings show that the earlier smokers with MS quit, the better the effect on progression in the long term. Data from the general population show that recovery after cessation is slow and incomplete. Smoking is associated with white matter hyperintensity progression 35 and accelerated cortical thinning. 36 Although partial recovery of cortical thinning is possible in ex-smokers, it takes time. 36 Epigenetic changes may be involved in the development and progression of MS 37 . Specific methylation status is sensitive and specific for smoking status. 38 Some methylation sites revert to levels typical of never smokers within decades, but others remain differentially methylated more than 35 years after smoking cessation. 39 In this study, we showed that the physical and psychological impact of MS from the patient perspective is worse in smokers than in nonsmokers. MSIS-29 17 physical and psychological scales measure related but distinct constructs, and it was suggested that a combined score may mask differential effects on physical and psychological health. 17 In our study, the unadjusted MSIS-29 scores showed an ascending trend from nonsmokers to current smokers when physical and psychological scales were measured separately but not for the overall score.
Overall, smokers fared worse on both physical and psychological MSIS-29 scales and on overall scores. The absolute differences in MSIS-29 scores between current and never smokers are likely to be clinically meaningful (>0.27 points on the MSIS-29 scale 1 to 5). Interestingly, the highest impact of smoking was noted on the MSIS-29 psychological scale. MSIS-29 psychological scale is more valid for detecting group differences in anxiety and depression, 17 and smoking is associated with increased risk of anxiety and depression in people with MS. 25, 40 Our study did not assess if smoking is a marker of risk or a causal factor for psychological change. Importantly, despite the belief among many smokers that quitting will lead to worsened mental health, smoking cessation is associated with reduced anxiety and depression. 25 Cognitive impairment occurs in approximatively half of all people with MS and typically involves information-processing speed, attention, working memory, and executive functions. 41 The MSIS-29 score is a predictor of self-efficacy in MS 42 , which in turn correlates with attention, reaction time variability, and speed of memory. 42 We have not assessed cognition in this group of patients. It would be of value in the future to consider the influence of smoking on cognition in people with MS.
Here, we show that the scores of the two patient-reported outcome measures MSIS-29 physical and PDDS were lower in ex-smokers than in current smokers. We suggest that MSIS-29 and PDDS are reliable measures for monitoring of people with MS undertaking smoking cessation interventions. MSIS-29 physical has been used in long-term phase III treatment studies. 19 The PDDS, a surrogate of EDSS, 18 is used in clinical research and practice alongside EDSS or when EDSS is impractical or costly. 18 Strengths of this study include the large cohort and the use of validated patient-based outcomes with questionnaires previously employed in MS. The main limitations of the study include the retrospective design (retrospective reports of smoking status with possibility of recall bias) and the low response rate (54%) making generalizability uncertain. Another limitation is the lack of biochemical verification of smoking status (eg, exhaled CO or urine nicotine/cotinine) in the participants to the study. The response rate in our study is similar to the response rate seen in other population questionnaire-based studies in MS. 43, 44 More of those who did not return the questionnaire could have been smokers. Smokers with MS have generally higher levels of disability 4 which could have precluded them from participating in the study, and smokers from disadvantaged groups tend to participate at lower rate in research studies. 45, 46 However, bias due to the response rate is less likely as the group of respondents was representative of the population studied (similar rates of smokers, ex-, and never smokers as the cohort in Manouchehrinia et al. 4 ). Moreover, this study focused on the impact of cessation in the respondents and not on the prevalence of smoking in the overall MS population. Another limitation is the reliance on self-reported adverse health behaviors, which may be susceptible to reporting bias, common to many similar studies. 25 Also, the cross-sectional assessment of the MS disability with MSIS-29 and PDDS questionnaires cannot provide information about how the impact of MS changes over time. Future studies assessing that impact at different time points could address this issue.
This study is novel in the effort to quantify the effect of smoking cessation. We provide for the first time estimates of the likelihood of reduction of progression in MS. These data can be used for calculation of sample size and effect size in intervention trials of smoking cessation in people with MS. Notably, the clear effect of smoking cessation on MS progression suggests the need to consider adjusting for smoking cessation when assessing for treatment effects in clinical trials of treatments in MS.
In conclusion, smoking cessation is associated with a significant reduction of the risk of disability progression. Smoking cessation should be an early intervention in people with MS.
